Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Decreases By 23.7%

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was the recipient of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 1,060,000 shares, a decrease of 23.7% from the February 13th total of 1,390,000 shares. Approximately 13.5% of the company’s stock are short sold. Based on an average trading volume of 92,200 shares, the days-to-cover ratio is presently 11.5 days.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in shares of Karyopharm Therapeutics by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock worth $942,000 after purchasing an additional 36,922 shares during the last quarter. Silverarc Capital Management LLC boosted its position in shares of Karyopharm Therapeutics by 6.7% during the 4th quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company’s stock worth $403,000 after acquiring an additional 37,524 shares in the last quarter. Velan Capital Investment Management LP purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at about $27,000. Two Sigma Advisers LP lifted its stake in Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after purchasing an additional 45,400 shares during the last quarter. Finally, Focus Partners Wealth acquired a new position in Karyopharm Therapeutics in the fourth quarter valued at approximately $31,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KPTI has been the topic of several research reports. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. HC Wainwright increased their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, February 26th. Royal Bank of Canada restated an “outperform” rating and issued a $45.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. Finally, Robert W. Baird decreased their target price on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Karyopharm Therapeutics Stock Down 2.1 %

Shares of KPTI traded down $0.12 during midday trading on Wednesday, reaching $5.71. The company had a trading volume of 10,683 shares, compared to its average volume of 73,917. The firm has a 50 day simple moving average of $8.93 and a 200-day simple moving average of $10.79. The stock has a market cap of $48.08 million, a PE ratio of -5.58 and a beta of 0.11. Karyopharm Therapeutics has a 1-year low of $5.56 and a 1-year high of $24.75.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating the consensus estimate of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. As a group, sell-side analysts anticipate that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).